Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$11.24 -5.3%	$11.69	$8.04 ▼ $45.00	$303.92M	2.36	450,897 shs	83,313 shs
ORKA Oruka Therapeutics	$9.43 -2.0%	$9.93	$5.49 ▼ $31.13	$352.84M	0.25	228,938 shs	23,705 shs
SLDB Solid Biosciences	$2.62 -6.1%	$3.68	$2.45 ▼ $10.46	$205.77M	2.32	1.02 million shs	450,107 shs
VIGL Vigil Neuroscience	$2.47 -2.2%	$1.94	$1.31 ▼ $6.06	$115.05M	1.9	475,799 shs	11,727 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+2.33%	+5.52%	+22.27%	-25.22%	-58.70%
ORKA Oruka Therapeutics	-1.33%	+3.55%	+25.26%	-18.96%	+961,999,900.00%
SLDB Solid Biosciences	-3.79%	-17.21%	+3.33%	-20.96%	-71.38%
VIGL Vigil Neuroscience	-0.40%	+4.56%	+69.13%	-6.32%	-30.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.8611 of 5 stars	4.6	0.0	2.6	2.5	0.6
ORKA Oruka Therapeutics	3.2756 of 5 stars	3.6	0.0	3.2	4.2	0.6
SLDB Solid Biosciences	3.9859 of 5 stars	3.7	4.0	3.8	3.3	1.3
VIGL Vigil Neuroscience	3.5212 of 5 stars	3.6	4.0	2.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.13	Buy	$58.80	423.36% Upside
ORKA Oruka Therapeutics	3.22	Buy	$39.86	322.89% Upside
SLDB Solid Biosciences	3.33	Buy	$15.67	497.96% Upside
VIGL Vigil Neuroscience	3.20	Buy	$16.25	559.23% Upside

Current Analyst Ratings Breakdown

Latest VIGL, SLDB, ARCT, and ORKA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/5/2025	VIGL Vigil Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00 ➝ $13.00
4/24/2025	VIGL Vigil Neuroscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/10/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/14/2025	VIGL Vigil Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $13.00
3/14/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $14.00
3/13/2025	SLDB Solid Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.00 ➝ $11.00
3/10/2025	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
3/10/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $68.00
3/10/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $20.00
3/7/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$63.00 ➝ $60.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$138.39M	2.20	N/A	N/A	$10.42 per share	1.08
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	$8.09M	25.10	N/A	N/A	$6.27 per share	0.42
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$3.24 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$29.73M	-$3.01	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	N/A
ORKA Oruka Therapeutics	-$5.34M	-$5.79	N/A	N/A	N/A	N/A	-24.96%	-21.22%	5/15/2025 (Estimated)
SLDB Solid Biosciences	-$96.01M	-$3.04	N/A	N/A	N/A	N/A	-58.75%	-47.84%	5/21/2025 (Estimated)
VIGL Vigil Neuroscience	-$82.64M	-$2.05	N/A	N/A	N/A	N/A	-83.89%	-65.34%	N/A

Latest VIGL, SLDB, ARCT, and ORKA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.57	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/7/2025	Q1 2025	VIGL Vigil Neuroscience	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A
3/13/2025	Q4 2024	VIGL Vigil Neuroscience	-$0.49	-$0.57	-$0.08	-$0.57	N/A	N/A
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million
3/6/2025	Q4 2024	ORKA Oruka Therapeutics	-$0.68	-$0.49	+$0.19	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	6.36%	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	4.76	4.76
ORKA Oruka Therapeutics	N/A	22.89	22.89
SLDB Solid Biosciences	N/A	7.85	7.85
VIGL Vigil Neuroscience	N/A	3.72	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
ORKA Oruka Therapeutics	56.44%
SLDB Solid Biosciences	81.46%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
ORKA Oruka Therapeutics	22.67%
SLDB Solid Biosciences	1.90%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
ORKA Oruka Therapeutics	N/A	37.44 million	27.07 million	N/A
SLDB Solid Biosciences	100	77.50 million	35.05 million	Optionable
VIGL Vigil Neuroscience	40	46.67 million	27.38 million	Not Optionable

VIGL, SLDB, ARCT, and ORKA Headlines

Recent News About These Companies

HC Wainwright Expects Higher Earnings for Vigil Neuroscience

May 13 at 1:13 AM | marketbeat.com

Q2 EPS Estimate for Vigil Neuroscience Increased by Analyst

May 13 at 1:13 AM | marketbeat.com

HC Wainwright Issues Optimistic Forecast for VIGL Earnings

May 13 at 1:04 AM | americanbankingnews.com

Wedbush Lifts Earnings Estimates for Vigil Neuroscience

May 13 at 1:04 AM | americanbankingnews.com

Vigil Neuroscience, Inc.: Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

May 7, 2025 | finanznachrichten.de

Wedbush Reaffirms Outperform Rating for Vigil Neuroscience (NASDAQ:VIGL)

May 7, 2025 | marketbeat.com

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

May 7, 2025 | globenewswire.com

Marshall Wace LLP Acquires 122,853 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

May 6, 2025 | marketbeat.com

Vigil Neuroscience Inc.

May 6, 2025 | barrons.com

Boothbay Fund Management LLC Makes New $249,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

May 5, 2025 | marketbeat.com

Renaissance Technologies LLC Has $624,000 Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

May 5, 2025 | marketbeat.com

683 Capital Management LLC Purchases 180,420 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

May 4, 2025 | marketbeat.com

Vigil Neuroscience (VIGL) Projected to Post Earnings on Tuesday

May 1, 2025 | marketbeat.com

Why Vigil Neuroscience, Inc.’s (VIGL) Stock Is Up 5.73%

April 30, 2025 | aaii.com

Vigil Neuroscience Stock Short Interest Report | NASDAQ:VIGL | Benzinga

April 30, 2025 | benzinga.com

Vigil Neuroscience (NASDAQ:VIGL) Upgraded by William Blair to "Strong-Buy" Rating

April 28, 2025 | marketbeat.com

Vigil presents data on oral small molecule program including VG-3927

April 3, 2025 | markets.businessinsider.com

William Blair Remains a Buy on Vigil Neuroscience Inc (VIGL)

April 3, 2025 | markets.businessinsider.com

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

April 2, 2025 | globenewswire.com

Vigil Neuroscience Reports 2024 Results and Clinical Progress

April 2, 2025 | tipranks.com

Vigil Neuroscience files to sell 5.38M shares of common stock for holders

April 1, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIGL, SLDB, ARCT, and ORKA Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$11.24 -0.63 (-5.27%)

As of 10:53 AM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Oruka Therapeutics NASDAQ:ORKA

$9.43 -0.20 (-2.03%)

As of 10:53 AM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Solid Biosciences NASDAQ:SLDB

$2.62 -0.17 (-6.09%)

As of 10:53 AM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Vigil Neuroscience NASDAQ:VIGL

$2.46 -0.06 (-2.18%)

As of 10:53 AM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time